Peregrine Capital Management LLC Sells 23,941 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Peregrine Capital Management LLC decreased its position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 10.9% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 196,033 shares of the company’s stock after selling 23,941 shares during the quarter. Peregrine Capital Management LLC owned 0.23% of Syndax Pharmaceuticals worth $4,236,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the company. Wellington Management Group LLP grew its holdings in shares of Syndax Pharmaceuticals by 2.7% in the 3rd quarter. Wellington Management Group LLP now owns 7,642,446 shares of the company’s stock worth $110,968,000 after purchasing an additional 198,262 shares during the last quarter. BlackRock Inc. grew its holdings in shares of Syndax Pharmaceuticals by 1.8% in the 2nd quarter. BlackRock Inc. now owns 4,990,984 shares of the company’s stock worth $104,461,000 after purchasing an additional 90,143 shares during the last quarter. State Street Corp grew its holdings in shares of Syndax Pharmaceuticals by 7.4% in the 2nd quarter. State Street Corp now owns 4,154,061 shares of the company’s stock worth $86,944,000 after purchasing an additional 287,831 shares during the last quarter. Finally, Vanguard Group Inc. grew its holdings in shares of Syndax Pharmaceuticals by 1.0% in the 3rd quarter. Vanguard Group Inc. now owns 3,617,302 shares of the company’s stock worth $52,523,000 after purchasing an additional 34,632 shares during the last quarter.

Syndax Pharmaceuticals Trading Up 1.4 %

Shares of NASDAQ:SNDX opened at $22.32 on Friday. The firm’s 50 day simple moving average is $22.88 and its 200 day simple moving average is $19.02. Syndax Pharmaceuticals, Inc. has a fifty-two week low of $11.22 and a fifty-two week high of $25.34.

Syndax Pharmaceuticals (NASDAQ:SNDX) last posted its earnings results on Tuesday, February 27th. The company reported ($1.00) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.99) by ($0.01). During the same period last year, the company earned ($0.62) earnings per share. Sell-side analysts predict that Syndax Pharmaceuticals, Inc. will post -3.7 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on SNDX shares. HC Wainwright reaffirmed a “buy” rating and issued a $41.00 target price on shares of Syndax Pharmaceuticals in a report on Wednesday, March 27th. Mizuho assumed coverage on shares of Syndax Pharmaceuticals in a research report on Friday, December 22nd. They set a “buy” rating and a $45.00 price target on the stock. StockNews.com upgraded shares of Syndax Pharmaceuticals to a “sell” rating in a research report on Friday, January 19th. Scotiabank downgraded shares of Syndax Pharmaceuticals from a “sector outperform” rating to a “sector perform” rating and reduced their price target for the stock from $36.00 to $23.00 in a research report on Wednesday, January 31st. Finally, JPMorgan Chase & Co. upped their price target on shares of Syndax Pharmaceuticals from $31.00 to $34.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 20th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $34.42.

Syndax Pharmaceuticals Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).